Global Search | Novartis

Hide Filters

Showing 2689 results

Press Release / Dec 08, 2024

Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2% vs. 47.1%), meeting both ASC4FIRST 96-week key…
Press Release / Dec 06, 2024

New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy

In the Phase IIIB APPULSE-PNH study, oral Fabhalta® (iptacopan) improved the average hemoglobin (Hb) level versus baseline in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were…
Partnering Event Calendar
Partnering Leadership Team
Research collaborations
Pulse Update / May 10, 2024

Novartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML
Pulse Update / Dec 02, 2024

Novartis bolsters Neuroscience pipeline with in-licensing of PTC518 for Huntington’s disease
Media Library / Nov 28, 2023

Lutz Hegemann, M.D., Ph.D.
Media Library / Nov 28, 2023

Lutz Hegemann, M.D., Ph.D.
Press Release / Nov 27, 2024

Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence

Approval is based on Phase III NATALEE data showing Kisqali® (ribociclib) plus adjuvant endocrine therapy (ET) demonstrated clinically meaningful invasive disease-free survival (iDFS) benefit in…